This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Saunders, Y Articles by Patel, S Search for Related Content PubMed PubMed Citation Articles by Saunders, Y Articles by Patel, S Pubmed/NCBI databases Medline Plus Health Information Cancer Social Bookmarking                         What's this?

Systematic review of bisphosphonates for hypercalcaemia of malignancy

J R Ross

K E Broadley

Department of Palliative Medicine, Royal Marsden Hospital, London

P M Edmonds

Department of Palliative Care and Policy, King's College Hospital, London

S Patel

Systematic Reviews Training Unit, Institute of Child Health, London

Background: Bisphosphonates are the treatment of choice for hypercalcaemia of malignancy (HCM) but there is no consensus regarding which drug or dose should be given. We designed a systematic review to investigate the efficacy of bisphosphonates in the treatment of HCM. Methods: We identified randomized controlled trials (RCTs) by searching electronic databases, scanning of reference lists, and consultation with experts and pharmaceutical companies. Foreign papers were translated. Inclusion criteria were RCTs, confirmed malignant disease and measurement of serum calcium (ionized or corrected for albumin) postrehydration. The primary outcome was number of patients achieving normocalcaemia. Secondary outcomes were time to normocalcaemia, time to relapse and toxicity. Results: Twenty-seven papers and two abstracts, using intravenous bisphosphonates, fulfilled the inclusion criteria. Data from 26 studies were used in analyses. Due to the heterogeneity of studies, meta-analysis could not be performed. Pamidronate was more effective than placebo, mithramycin, etidronate (7.5 mg/kg) and low-dose clodronate (600 mg), but equal to higher dose clodronate (1500 mg). Clodronate and etidronate were superior to placebo; incadronate was superior to elcatonin; gallium nitrate was superior to etidronate. No difference was seen between alendronate and clodronate. Three dose finding studies showed no difference between 30–90 mg of pamidronate, but one well designed study showed increasing efficacy with increasing dose. Studies using increasing doses of ibandronate (0.6–4 mg), alendronate (2.5–15 mg), and incadronate (2.5–10 mg), showed a dose response. Duration of administration of pamidronate did not affect efficacy (six studies). Conclusion: Bisphosphonates normalize calcium in 70% patients with minimal side effects. Aminobisphosphonates are most effective at maintaining normocalcaemia and should be given in high dose irrespective of baseline serum calcium.

Palliative Medicine, Vol. 18, No. 5, 418-431 (2004)
DOI: 10.1191/0269216304pm914ra


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. McMahan and T. Linneman A Case of Resistant Hypercalcemia of Malignancy with a Proposed Treatment Algorithm Ann. Pharmacother., September 1, 2009; 43(9): 1532 - 1538. [Abstract] [Full Text] [PDF]

				A. Liberati, D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gotzsche, J. P.A. Ioannidis, M. Clarke, P. J. Devereaux, J. Kleijnen, and D. Moher The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration Ann Intern Med, August 18, 2009; 151(4): W-65 - W-94. [Abstract] [Full Text] [PDF]

				A. Liberati, D. G Altman, J. Tetzlaff, C. Mulrow, P. C Gotzsche, J. P A Ioannidis, M. Clarke, P J Devereaux, J. Kleijnen, and D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ, July 21, 2009; 339(jul21_1): b2700 - b2700. [Abstract] [Full Text]

				S. B. LeGrand, D. Leskuski, and I. Zama Narrative Review: Furosemide for Hypercalcemia: An Unproven yet Common Practice Ann Intern Med, August 19, 2008; 149(4): 259 - 263. [Abstract] [Full Text] [PDF]

				N Walji, A K Chan, and D R Peake Common acute oncological emergencies: diagnosis, investigation and management Postgrad. Med. J., August 1, 2008; 84(994): 418 - 427. [Abstract] [Full Text] [PDF]

				T. R. Halfdanarson, W. J. Hogan, and T. J. Moynihan Oncologic Emergencies: Diagnosis and Treatment Mayo Clin. Proc., June 1, 2006; 81(6): 835 - 848. [Abstract] [Full Text] [PDF]